Provided by Tiger Trade Technology Pte. Ltd.

Nurix Therapeutics

22.99
-0.3500-1.50%
Post-market: 22.990.00000.00%19:30 EDT
Volume:815.51K
Turnover:18.85M
Market Cap:2.38B
PE:-6.74
High:23.75
Open:23.72
Low:22.85
Close:23.34
52wk High:28.23
52wk Low:8.99
Shares:103.41M
Float Shares:74.11M
Volume Ratio:0.44
T/O Rate:1.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4102
EPS(LYR):-3.0514
ROE:-80.30%
ROA:-40.06%
PB:5.90
PE(LYR):-7.53

Loading ...

Shares of Nurix Therapeutics up 57.1% Premarket After $2 Bln Cancer Drug Agreement With Roche

THOMSON REUTERS
·
Jun 08

Roche enters $2 billion cancer drug agreement with Nurix Therapeutics

Reuters
·
Jun 08

PRESS DIGEST -Wall Street Journal - June 8

Reuters
·
Jun 08

Roche To Collaborate With Nurix Therapeutics On BTK Degrader Bexobrutideg

Reuters
·
Jun 08

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

GlobeNewswire
·
Jun 08

Nurix Therapeutics Chief Legal Officer Christine Ring sells 8,148 shares for $135,226.72

Reuters
·
Jun 03

Nurix Therapeutics Price Target Maintained With a $30.00/Share by BTIG

Dow Jones
·
May 18

Nurix Therapeutics Shareholders Back Directors and Governance Proposals

TIPRANKS
·
May 16

Nurix Therapeutics shareholders ratify PwC as auditor for fiscal 2026

Reuters
·
May 16

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

GlobeNewswire
·
May 15

Nurix Therapeutics (NRIX) Receives a Buy from Oppenheimer

TIPRANKS
·
May 13

Piper Sandler Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)

TIPRANKS
·
May 13

Nurix CEO Sands to join RBC Global Healthcare Conference fireside chat

Reuters
·
May 13

Nurix Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 13

BRIEF-Nurix Therapeutics Announces Bexobrutideg Oral Presentation

Reuters
·
May 13

Nurix to present updated Phase 1 data for BTK degrader bexobrutideg in CLL at EHA2026

Reuters
·
May 13

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

THOMSON REUTERS
·
May 13

Nurix CFO Hans van Houte disposes of common shares worth $233,463.29

Reuters
·
May 06

Nurix Chief Legal Officer Christine Ring disposes 8,148 shares worth $138,205

Reuters
·
May 05

Is Nurix’s Pan-Mutant BRAF Degrader Data Reshaping The Investment Case For Nurix Therapeutics (NRIX)?

Simply Wall St.
·
May 03